Bronchopulmonary Dysplasia (BPD) Epidemiology Insights

Thelansis’s “⁠Bronchopulmonary Dysplasia (BPD) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic respiratory morbidity of prematurity, predominantly afflicting extremely low birth weight (ELBW) infants born prior to 28 weeks of gestation. In the modern post-surfactant era, the pathogenesis of “new BPD” is fundamentally characterized by a critical arrest of both alveolarization and pulmonary microvascular development—resulting in fewer, larger, and highly simplified alveoli—driven by the synergistic, iatrogenic insults of mechanical ventilation (volutrauma and barotrauma) and oxygen toxicity acting upon a profoundly immature and highly inflammatory respiratory system. Clinically defined by a sustained requirement for supplemental oxygen or positive pressure respiratory support at 36 weeks post-menstrual age, the disease initiates a catastrophic cascade that heavily predisposes surviving infants to lifelong sequelae, most notably severe pulmonary hypertension, reactive airway disease, and significant neurodevelopmental impairment. Because definitive pharmacological cures remain elusive, the modern therapeutic paradigm relies heavily on aggressive prevention and lung-protective strategies. The standard of care strictly prioritizes the avoidance of invasive intubation by leveraging early non-invasive continuous positive airway pressure (CPAP), synergistically combined with targeted exogenous surfactant replacement, caffeine citrate therapy, optimized nutritional fortifiers, and the highly judicious administration of postnatal systemic or inhaled corticosteroids to mitigate rampant inflammation and facilitate successful weaning from respiratory support.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)